thought call
result didnt broadli beat street expect revenue ep
merck stori continu root aggress growth keytruda franchis
consist assert domin continu
long-term across major solid tumor notabl nsclc rcc attribut today
weak hit high expect keytruda beat well
languag suggest anim health franchis remain in-hous
short-sight concern view latter need broaden product mix
divers away oncolog spin-off ah would strateg sub-optim
view i/o despit merck domin space share havent seen much
upsid sinc meet april like reflect moder ramp
keytruda revenu expect look forward howev lung stori
begin play eventu renal suspect merck see consist
robust keytruda upsid continu like merck posit rel peer
pipelin perspectiveswith ad emphasi sharehold return
evidenc today share repurchas announcementand look
out-performance keytruda stori continu manifest model total
revenu support overweight rate price target
pipelin progress dmc review data expect sometim phase kn-
neoadjuvant/adjuv tnbc addit phase dataset keytruda across
tnbc esophag expect cours near-term regulatori
approv includ lung month lung monotherapi
januari adj melanoma februari novemb
lynparza metastat breast cancer eu also point mid
novemb first time data early-stag anti-tigit asset
model chang made adjust model reflect perform
updat guidanc well manag commentari today call
chang ep estim move
unchang revenu move
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight believ merck like
continu take share lung back
posit data addit
view perhap first-lin lung
market share grab us support
ow rate
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit pipelin data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg barclay merck co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
